Wedbush Maintains Outperform on Denali Therapeutics, Lowers Price Target to $26
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico maintains an Outperform rating on Denali Therapeutics (NASDAQ:DNLI) but lowers the price target from $30 to $26.
August 02, 2024 | 1:53 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Wedbush analyst Laura Chico maintains an Outperform rating on Denali Therapeutics but lowers the price target from $30 to $26.
The Outperform rating suggests a positive outlook, but the lowered price target indicates some tempered expectations. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100